About Basilea PharmaceuticaBasilea Pharmaceutica is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.
October 17, 2000
Founder: Jan G. J. van de Winkel, Ph.D.
CEO: Ronald Scott
CMO (Medical): Achim Kaufhold
CTO: Günter Ditzinger
CFO: Donato Spota
CSO (Scientific): Laurenz Kellenberger
Please click here for.
Please click here for clinical trial information.
212 articles with Basilea Pharmaceutica
Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress
Basilea Pharmaceutica Ltd. announced the reporting of the updated efficacy and safety results from cohort 1 of the phase 2 study FIDES-01, which evaluated its fibroblast growth factor receptor inhibitor, derazantinib, in patients with FGFR2 fusion-positive advanced or metastatic intrahepatic cholangiocarcinoma, a type of bile duct cancer, at the Congress of the European Society for Medical Oncology, taking place as a virtual meeting from 16 to 21 September 2021.
Basilea reports strong financial results for half-year 2021 with significantly increased cash flow from marketed brands and increases 2021 full-year guidance
Basilea Pharmaceutica Ltd. announced its financial results for the first six months ended June 30, 2021.
Basilea Pharmaceutica Ltd. announced that it has been awarded an additional USD 4.3 million of non-dilutive funding by the Biomedical Advanced Research and Development Agency, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in the context of the existing contract to support the phase 3 program of Basilea’s antibiotic ceftobiprole.
Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma
Basilea Pharmaceutica Ltd. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Basilea’s tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma.
Basilea’s partner Asahi Kasei Pharma prepares NDA filing for the marketing authorization of isavuconazole in Japan based on positive phase 3 study results
Basilea Pharmaceutica Ltd. reported that its partner Asahi Kasei Pharma Corporation is planning to file a New Drug Application for the marketing authorization of the antifungal isavuconazole in Japan, based on the positive results of the recently completed phase 3 study in deep-seated mycoses.
Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) covering Russia and the Eurasian Economic Union
Basilea Pharmaceutica Ltd. announced that it has entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Basilea’s antibiotic Zevtera® in Russia, as well as in the other countries of the Eurasian Economic Union.
Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO Annual Meeting
Basilea Pharmaceutica Ltd. announced that data on the prevalence of end-binding protein 1 in glioblastoma and other tumor types is being presented at the American Society of Clinical Oncology Annual Meeting that takes place online from June 4 to 8, 2021.
Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clinical programs in urothelial and gastric cancer
An updated analysis shows further improvement of progression-free survival, disease control rate and objective response rate in the cohort of FGFR2 gene fusion-positive patients with bile duct cancer (iCCA) in FIDES-01 study
Basilea Pharmaceutica Ltd. announced that it has been awarded a grant of up to USD 2.7 million from CARB-X, a global partnership dedicated to supporting the early development of antibacterial products to diagnose, prevent and treat drug-resistant infections.
8/12/2019Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
Basilea Pharmaceutica, based in Basel, Switzerland, announced positive topline data from its Phase III TARGET study of deftobiprole for acute bacterial skin and skin structure infections.
CRESEMBA™ now available in Canada for the treatment of invasive aspergillosis and invasive mucormycosis
AVIR Pharma Inc., is pleased to announce that Cresemba™ is now available in Canada.
Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
Basilea Pharmaceutica Ltd. announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study in mid-2019.
Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)
ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica (SIX: BSLN), today announced results from the interim analysis of the registrational Phase 2 study with the orally administered pan-fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib (BAL087).
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China
ArQule eligible to receive up to $336 million including upfront, regulatory and commercial milestone payments
Basilea Announces Completion of the License Agreement Extension With Pfizer for Antifungal Cresemba for China and Asia Pacific
The amendment was subject to customary regulatory review which has completed. Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections.
Basilea Reports Start of Clinical Phase I Study in Collaboration With the U.S. Adult Brain Tumor Consortium to Explore BAL101553 in Newly Diagnosed Glioblastoma
Patients participating in the study have a reduced sensitivity to standard chemotherapy with temozolomide due to an unmethylated MGMT promoter.
Basilea Reports That Ceftobiprole Received QIDP Designation From U.S. FDA for the Treatment of Staphylococcus Aureus Bacteremia (SAB)
Basilea announced today that the U.S. FDA designated its investigational drug ceftobiprole as a QIDP.
Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA (isavuconazole) in China and Asia Pacific Region
Pfizer and Basilea Pharmaceutica announced they have entered into an agreement whereby Pfizer will be granted the exclusive development and commercialization rights in China and several countries in the Asia Pacific region to CRESEMBA (isavuconazole).
Basilea eligible to receive additional upfront and milestone payments of up to USD 226 million and mid-teen royalties on sales.